Skip to content
  • About Us
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Leadership Team
    • Board
    • Management Team
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact Us
  • About Us
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Leadership Team
    • Board
    • Management Team
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact Us

Day: July 13, 2021

Bioshares Interview: Malcolm McColl, CEO ImmVirX

Bioshares

Bioshares recently interviewed our CEO Malcolm McColl as part of their latest edition.‍ You can read the full story in PDF format here.‍

Join Our Mailing List

Our mission is to develop receptor-targeted oncolytic RNA immunotherapies that improve outcomes for patients with cancers that are difficult to treat

About Us
Our Technology
Immvirx logo
A clinical-stage company developing receptor-targeted oncolytic RNA immunotherapies for cancers with high unmet need.
Twitter Linkedin
Company
  • About Us
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Leadership Team
    • Board
    • Management Team
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact Us
  • About Us
    • Oncolytic Viruses
    • Immunotherapy Combinations
    • R&D Facility
    • Team
    • Company News
    • Corporate Investor Deck
  • Our Technology
    • IVX037
    • IVX055
    • Pipeline
    • Scientific Presentations
    • Pre-clinical / discovery
  • Clinical
    • Therapeutic Strategy
    • Innovent Collaboration
    • Pipeline
  • Leadership Team
    • Board
    • Management Team
  • Investor Centre
    • Corporate Deck
    • Company Announcements
    • In the News
    • ESG
  • Recruitment
  • Contact Us

© 2026 ImmVirX Pty Ltd • Website developed by Noise